BUND FINANCE

BUND FINANCE › Stocks › MRNA

Moderna, Inc. (MRNA)

NASDAQ · Stock price, chart and technical analysis

US$196.79-10.01 (-4.84%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$206.80
OpenUS$206.80
Day rangeUS$196.53 – US$208.68
52-week rangeUS$22.28 – US$280.80
Market capUS$79.63B
Volume6.91M
50-day averageUS$204.39
200-day averageUS$98.09
Beta0.90

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$17.7BUS$18.9BUS$6.8BUS$3.2BUS$1.9B
Net incomeUS$12.2BUS$8.4B−US$4.7B−US$3.6B−US$2.8B
EPS (diluted)28.2920.10-12.34-9.27-7.26
Gross margin85.2%71.3%31.5%54.2%55.4%
Operating margin75.0%49.9%-61.9%-123.3%-158.1%
Net margin68.8%44.3%-68.8%-111.3%-145.2%
Free cash flowUS$13.3BUS$4.6B−US$3.8B−US$4.1B−US$2.1B
Total debtUS$916.0MUS$1.2BUS$1.2BUS$747.0MUS$1.3B
CashUS$6.8BUS$3.2BUS$2.9BUS$1.9BUS$2.6B

Compound annual growth: revenue -42.5% · net income — (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E—8.4x27.1x
EV / EBITDA—7.0x16.5x
Operating margin-116.0%—3.6%
Net margin-110.5%—-0.0%
Debt / equity0.97—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Moderna, Inc.

SectorHealthcare
IndustryBiotechnology
CountryUS
CEOStéphane Bancel
Employees4,700
IPO date2018-12-07

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr vi…

www.modernatx.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice